Heading to outer space anytime soon? You may be dining on cultivated meat, thanks to a new partnership between Micro Meat, and Orbital Assembly, developer of space-based business parks with variable gravity.
https://t.co/g9Wn9pK0Cv
@GreenQueenHK
Join SVLC Managing Partner, @chvalverdep and Jon Belgrad, Officer/Miami of the Knight Foundation at Culture Shifting Weekend in Miami on Friday, October 14th.
We are elated to announce that Vartan Indjeian has joined our team as CFO! We believe his knowledge, experience and passion for startups will contribute to SVLC's pathway forward. 🚀
Great panel today at #CultureShiftingSummit on Diverse Fund Managers Fundraising, Driving Returns and LatAm markets featuring our Managing Partner, @chvalverdep & moderated by @sarahkunst of @cleocapital
Mark your calendars for @_howwomenlead 's panel featuring @SVLC Founder & Managing Partner, @chvalverdep!
This session will shed light on the power and influence of investing and its direct effects on systemic change in leadership.
https://t.co/fCXMDaBhXf
@HowWomenInvest
🧠 Muy agradecido a @lanacionmas y @LANACION por haber participado de este Evento sobre Economía basada en conocimiento
Feliz de poder contar cómo BIOMAKERS crece semana a semana a nivel global e impacta a miles de pacientes a través de la Tecnología y la Medicina de Precisión
It was a pleasure to participate in the panel: “Determining the Extent the Understandings Gained from Covid19 ARDS Can Be Translated Into ARDS” at the #ARDSDrugDevelopmentSummit2022. We leave the conference even more charged to further accelerate a novel therapy for #ARDS#ai
🚀 Estamos sumamente orgullosos de que BIOMAKERS se haya convertido en una de las Compañías de Medicina de Precisión y Tecnología en Cáncer & Enfermedades Poco Frecuentes de mayor impacto global de los últimos años
We are thrilled to announce our investment in Holoclara's Series A! Founded by Caltech and Cornell scientists, Holoclara is developing first-in-class drugs for allergic and autoimmune diseases using round-worm derived therapeutic compounds.
Thrilled to share that Thomas Ebeling is now a seed investor in @gen1elifesci. Earlier in his career, Thomas served as CEO of @Novartis, during which it doubled its revenues. He served on the supervisory board of @Bayer and @LonzaGroup. Thank you, Thomas, for your support!
Typically, it takes up to 10 years and around $400 million to launch a new product in advanced materials. @aresmaterials went from product identification to customer acceptance in less than 18 months.
CEO – @arreaga85
https://t.co/arb2h8PS7B
Thrilled to announce that Jaime Roblesgil, Former Head of Latin American Markets of Citi Group has joined our portfolio company, Fiado, as Co-Founder and CEO.
https://t.co/WythPvGLwa
@Correlia_Bio has catalyzed a tangible paradigm shift within the scientific community with their protein biomarker quantitation, allowing pharma companies to create drugs faster and more efficiently.
https://t.co/N2ZZTELlBQ
@CrystalNyitray and @GraceWei1 shared an idea about creating living medicines for a patient when the patient needs them. The resulting company, @Encellin_Inc, leverages cells as molecular factories.
https://t.co/MYXi2fRp4j
Innovation is urgently needed to combat the coffee industry’s contributions to climate change. @maricelsaenz's solution was to launch @CompoundFoods
https://t.co/7ONqZrkvi6